:

: ?

MCC ( ): . .

: '
14/11/17
5 5 ( 2)

: (EMA) , (), (MCC) .

(MCC)?

MCC , . (FDA) , .

      -   . : thinkstock

- . : thinkstock

?

- " ".

, , - ( ).

, . , , 2017 - , .

? ?

" -FDA " -EMA 2, . - MCC . : , .

- , - . lancet oncology ' . 2016.

, , . , - " . '', -ASCO ; -ESMO .

( , ), " " '' -ESMO, -71% , 6 ; -7% , .

, , " ' , -33% ; -10% , .

, , . . , , - .

? ? ?

, . , - basal cell carcinoma (BCC), squamous cell carcinoma (SCC), - - .

MCC - ?

, merkel cell carcinoma (MCC) - ( ), .

, -MCC , . , - .

MCC " " , - , .

, -40 MCC . , -12-15 MCC . : 0.13-0.35 100,000 .

    ,     . : thinkstock

, . : thinkstock

?

() ; , checkpoint inhibitors Anti PDL1. , .

, . () - .

, . . , . , , - .

: , - , , . , - .

' ' , -; , -.

: 14/11/17

:

DOCTORS